Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?

This is a great question. In phase II prospective study, Gomez and colleagues (Gomez et al., PMID 31067138) demonstrated a PFS and OS benefit with local consolidative therapy in patients whose disease did not progress after first-line systemic therapy. In my opinion, local consolidation therapy to o...

For truly polymetastatic patients, I tend to take an approach of consolidation of oligoprogressive or oligoresistant lesions while these patients continue on highly effective systemic therapy. Driver mutations adenos can have durable responses to generally well-tolerated therapy for many years and w...